Recurrence and Tailoring Radiotherapy Following Neoadjuvant Chemotherapy

Article

Eleftherios Mamounas, MD, MPH, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.

Clinical Pearls

Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses locoregional recurrence and tailoring radiotherapy following neoadjuvant chemotherapy.

  • Researchers are trying to understand whether the response and tumor subtype of patients treated with neoadjuvant chemotherapy can help to tailor the use of radiotherapy afterwards.
  • Though the data from this analysis do not provide a definitive answer, they help researchers understand that these patients had low rates of recurrence and tailoring radiotherapy is possible. Trials are in progress to test this concept.

<<<

Back to the 2014 Breast Cancer Symposium conference page

Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content